AstraZeneca executives were adamant that detailed data from a phase 3 study of the pharma’s next-generation antibody-drug ...
Roche has shed more light on its investigational KRAS G12C inhibitor's phase 3 victory over Amgen’s Lumakras and Bristol Myers Squibb’s Krazati. | Roche has shed more light on its investigational KRAS ...
The Big Pharma has already launched a phase 2 trial of JNJ-6143 at a 50 mg daily dose in around 100 patients with metastatic androgen pathway modulation-resistant prostate cancer (mAPMR), an advanced ...
Merck & Co. and Moderna always knew they would be making headlines in Madrid this week—just not in the way it panned out. | Merck & Co. and Moderna always knew they would be making headlines in Madrid ...
Eli Lilly has shared phase 1 data on an antibody-drug conjugate (ADC) in platinum-sensitive ovarian cancer (PSOC), shedding light on the company’s chances of competing for a market targeted by rivals ...
Bolt Biotherapeutics is acquiring Prana Therapies in a stock-for-stock reverse merger aimed at advancing Prana’s pipeline of antibodies targeting inflammatory conditions. | Bolt Biotherapeutics is ...
Takeda has lifted the lid on the phase 3 win for its next-generation claudin18.2 drug, with the antibody-drug conjugate (ADC) demonstrating overall survival (OS) of 10.2 months in tough to treat ...
Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the ...
| Pathos AI has closed a $237 million series E round led by pharma giant Bristol Myers Squibb on the same day that the two companies signed a cutting-edge Alzheimer's disease-focused collaboration.
Despite the sweeping scope of the ban covering various types of drug molecules, biopharma business development teams can ...
Merck & Co. and Moderna have shared highly anticipated phase 3 data on their cancer vaccine, revealing a primary endpoint hit ...
Celltrion has licensed a preclinical antibody aimed at autoimmune conditions from Maryland-based biotech Kaigene in a deal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results